NIMBEX PRESERVATIVE FREE Drug Patent Profile

When do Nimbex Preservative Free patents expire, and when can generic versions of Nimbex Preservative Free launch?

Nimbex Preservative Free is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in NIMBEX PRESERVATIVE FREE is cisatracurium besylate. There are nine drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the cisatracurium besylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nimbex Preservative Free

A generic version of NIMBEX PRESERVATIVE FREE was approved as cisatracurium besylate by SANDOZ INC on February 3^rd, 2012.

Summary for NIMBEX PRESERVATIVE FREE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	63
Patent Applications:	715
DailyMed Link:	NIMBEX PRESERVATIVE FREE at DailyMed

Paragraph IV (Patent) Challenges for NIMBEX PRESERVATIVE FREE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NIMBEX PRESERVATIVE FREE	Injection	cisatracurium besylate	2 mg/mL, 10 mL vial	020551	1	2009-08-12
NIMBEX PRESERVATIVE FREE	Injection	cisatracurium besylate	2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial	020551	1	2009-08-04

US Patents and Regulatory Information for NIMBEX PRESERVATIVE FREE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	NIMBEX PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	020551-003	Dec 15, 1995		DISCN	Yes	No
Abbvie	NIMBEX PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	020551-002	Dec 15, 1995		DISCN	Yes	No

Expired US Patents for NIMBEX PRESERVATIVE FREE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	NIMBEX PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	020551-003	Dec 15, 1995	4,179,507
Abbvie	NIMBEX PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	020551-002	Dec 15, 1995	5,453,510
Abbvie	NIMBEX PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	020551-002	Dec 15, 1995	4,179,507
Abbvie	NIMBEX PRESERVATIVE FREE	cisatracurium besylate	INJECTABLE;INJECTION	020551-003	Dec 15, 1995	5,453,510

International Patents for NIMBEX PRESERVATIVE FREE

See the table below for patents covering NIMBEX PRESERVATIVE FREE around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	61485
New Zealand	238964	GEOMETRICALLY AND OPTICALLY PURE 1R-CIS,1'R-CIS ATRACURIUM SALTS, PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF
Japan	3462165
France	2665701	AGENTS DE BLOCAGE NEUROMUSCULAIRE.

NIMBEX PRESERVATIVE FREE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for NIMBEX Preservative Free

Introduction to NIMBEX

NIMBEX, also known as cisatracurium, is a nondepolarizing neuromuscular blocking agent used as an adjunct to general anesthesia to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation[1][4].

Market Size and Growth

The global neuromuscular blockade drugs market, which includes NIMBEX, was valued at USD 5.23 billion in 2023 and is projected to reach USD 7.44 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 4.50% during the forecast period of 2024 to 2031[3].

Drivers of Market Growth

Increasing Surgical Procedures

The demand for neuromuscular blockade drugs like NIMBEX is driven by the increasing number of surgical procedures worldwide, particularly in fields such as orthopedics, cardiovascular surgery, and oncology. These procedures require muscle relaxation to enhance surgical outcomes and reduce complications[3].

Rising Geriatric Population

The growing geriatric population is another significant driver. Older patients often require more surgical interventions, which in turn increases the demand for neuromuscular blockade agents[3].

Advancements in Healthcare Infrastructure

Improvements in healthcare infrastructure, especially in emerging economies, and the introduction of novel neuromuscular blockade drugs are expected to further drive market growth. The focus on research and development to enhance the safety and efficacy of these drugs also contributes to the market's expansion[3].

Regional Analysis

North America

North America is expected to dominate the market due to its well-established healthcare infrastructure, increased focus on research and development, and the presence of leading pharmaceutical companies and research institutions[3].

Global Market Coverage

The market is analyzed across various regions including the U.S., Canada, Mexico, Germany, France, the U.K., and several countries in Asia-Pacific, Middle East, and Africa. Each region presents unique opportunities and challenges for the growth of the neuromuscular blockade drugs market[3].

Competitive Landscape

NIMBEX competes in a market that includes other nondepolarizing neuromuscular blocking agents such as rocuronium, atracurium, vecuronium, and pancuronium. Each of these drugs has its own profile of onset time, duration of action, and side effects, which influence their market share and usage[3].

Dosage and Administration

The dosage of NIMBEX varies based on the patient population and the clinical setting. For adult patients, the recommended initial dose is typically 0.15 to 0.2 mg/kg, with maintenance bolus doses of 0.03 mg/kg as needed. For pediatric patients, the doses range from 0.1 to 0.15 mg/kg[1][4].

Clinical Considerations

Burn Patients

Burn patients may develop resistance to nondepolarizing neuromuscular blocking agents, necessitating higher doses of NIMBEX for both intubation and maintenance[1][4].

Inhalational Anesthetics

The use of inhalational anesthetics can affect the dosing and duration of action of NIMBEX. For example, during stable isoflurane anesthesia, the infusion rate of NIMBEX may need to be reduced by up to 30% to 40%[1][4].

Adverse Events and Safety

NIMBEX, like other neuromuscular blocking agents, can be associated with several adverse events. Common adverse reactions include bradycardia, hypotension, flushing, bronchospasm, and rash. Serious adverse events such as anaphylactic reactions and cardiac arrest have also been reported[5].

Financial Trajectory

The financial trajectory of NIMBEX is closely tied to the overall growth of the neuromuscular blockade drugs market. As the market expands due to increasing surgical procedures, a growing geriatric population, and advancements in healthcare infrastructure, the revenue generated by NIMBEX is expected to increase.

Revenue Projections

Given the market's projected growth from USD 5.23 billion in 2023 to USD 7.44 billion by 2031, NIMBEX, as a key player in this market, is likely to see a significant increase in its revenue. This growth will be driven by increased adoption in surgical settings and critical care units.

Key Takeaways

• The global neuromuscular blockade drugs market is expected to grow at a CAGR of 4.50% from 2024 to 2031.
• NIMBEX is a critical component of this market, used for its efficacy in providing muscle relaxation during surgery and mechanical ventilation.
• The drug's usage is influenced by factors such as the type of anesthesia used, patient population (including burn patients), and the need for precise dosing to avoid adverse events.
• North America is expected to dominate the market due to its advanced healthcare infrastructure and research focus.
• The financial trajectory of NIMBEX is positive, with projected revenue growth aligned with the expanding market.

FAQs

Q: What is NIMBEX used for? A: NIMBEX is used as an adjunct to general anesthesia to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Q: What are the common adverse events associated with NIMBEX? A: Common adverse events include bradycardia, hypotension, flushing, bronchospasm, and rash. Serious adverse events such as anaphylactic reactions and cardiac arrest have also been reported.

Q: How does the use of inhalational anesthetics affect NIMBEX dosing? A: The use of inhalational anesthetics can require adjustments to the dosing and infusion rate of NIMBEX, such as reducing the infusion rate by up to 30% to 40% during stable isoflurane anesthesia.

Q: What are the recommended doses of NIMBEX for pediatric patients? A: For pediatric patients aged 2 to 12 years, the recommended weight-based bolus dose of NIMBEX is 0.1 to 0.15 mg/kg administered over 5 to 10 seconds.

Q: Why is North America expected to dominate the neuromuscular blockade drugs market? A: North America is expected to dominate the market due to its well-established healthcare infrastructure, increased focus on research and development, and the presence of leading pharmaceutical companies and research institutions.

Cited Sources

1. Drugs.com: Nimbex: Package Insert / Prescribing Information.
2. Medicines.org.uk: Cisatracurium 2mg/ml solution for injection/infusion.
3. Data Bridge Market Research: Global Neuromuscular Blockade Drugs Market Size, Demand & Research.
4. FDA: Reference ID: 5060537 - NIMBEX Prescribing Information.
5. Frontiers in Pharmacology: Adverse events related to neuromuscular blocking agents.